Quince Therapeutics, Inc. (QNCX)
| Market Cap | 15.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.16M |
| Shares Out | 16.30M |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,100 |
| Open | 0.947 |
| Previous Close | 0.976 |
| Day's Range | 0.928 - 1.015 |
| 52-Week Range | 0.790 - 45.499 |
| Beta | 1.37 |
| Analysts | Buy |
| Price Target | 4.00 (+323.95%) |
| Earnings Date | Aug 10, 2026 |
About QNCX
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a dr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for QNCX stock is "Buy." The 12-month stock price target is $4.0, which is an increase of 323.95% from the latest price.
News
Quince Therapeutics initiated with an Outperform at Leerink
Leerink analyst Joseph P. Schwartz initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $4 price target Following its acquisition of Orphai Therapeutics, Quince has repositio...
Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Quince Therapeutics (QNCX) with an Overweight rating and $4 price target The firm believes Quince offers one of the more compelli...
Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Quince Therapeutics (QNCX) with an Overweight rating and $4 price target
UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),...
Quince Therapeutics Transcript: Investor update
Announced the acquisition of Orphai and a $150M private placement to fund LAM-001, an inhaled rapamycin for multiple rare lung diseases. Phase II-A data in PH-ILD showed promising efficacy and safety, with key clinical milestones expected through 2028.
Quince Therapeutics Press release: Investor update
Quince Therapeutics issued a press release on May 18, 2026, disclosing material business information to investors.
Quince Therapeutics Slides: Investor update
Quince Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Quince Therapeutics announces LAM-001 data
Quince Therapeutics (QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin, in patients with pulmonary arterial hypertension and pulmonary hypertension associated with ...
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
Quince Therapeutics (QNCX) announced it has acquired Orphai Therapeutics. The acquisition brings Orphai’s program LAM-001, an inhaled formulation of rapamycin, to treat rare pulmonary diseases, into Q...
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced it has acquired Orphai Therapeutics Inc., a clinical-stage biotechnology company. The a...
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor),...
Quince Therapeutics Slides: Investor presentation
Quince Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
Quince Therapeutics Quarterly report: Q1 2026
Quince Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics trading halted, news pending
19:50 EDT Quince Therapeutics (QNCX) trading halted, news pending
Quince Therapeutics Annual report: Q4 2025
Quince Therapeutics has published its Q4 2025 annual report on April 10, 2026.
Quince Therapeutics settles $16.4M of debt
Quince Therapeutics (QNCX) announced the settlement of the company’s outstanding obligations under its loan from the European Investment Bank for a payment of $5.5M. Effective immediately upon the $5....
Quince Therapeutics Settles Approximately $16.4 Million of Debt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its l...
Why Is Quince Therapeutics Stock (QNCX) Up Today?
Quince Therapeutics stock was up on Tuesday after it announced plans to explore strategic alternatives.
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advis...
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog...
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog...
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog...